NIH Names John Powers to Lead Infectious Disease Institute
John Powers, a longtime National Institute of Allergy and Infectious Diseases physician and researcher, has been appointed the institute’s permanent director by NIH Director Jay Bhattacharya. Powers had served as acting director since June. He is the institute’s fourth director in four years and succeeds an agency long led by Anthony Fauci, who held the post for nearly four decades.
Bhattacharya said the agency would move away from biodefense research and focus more on immunology and infectious diseases that affect people in the United States. In fiscal year 2025, biodefense programs represented roughly 33 percent of NIAID’s funding, exceeding $2.2 billion. Those programs are being transferred to the Department of War, Bhattacharya said.
Bhattacharya and Powers said they reviewed more than 8,000 research grants to identify laboratory work involving dangerous experiments. The change follows years of disputes over the use of public funds for biodefense research, including questions raised during the COVID-19 pandemic about whether US-funded work in China could have contributed to the virus’s emergence. Fauci has denied that his agency funded dangerous experiments at the Wuhan Institute of Virology; scientists have disputed his account or said the research cannot be determined with certainty.
Powers said NIAID would support research to answer medical questions, including those about masks, rather than set public policy. He also said the institute would emphasize getting established interventions to patients, pointing to the progress that has made once-fatal HIV manageable with a daily pill. Bhattacharya said NIH is working with Congress to provide records from the pandemic period.
NIH’s New NIAID Chief Puts Research Ahead of Pandemic Politics
The NIH has named John Powers to lead the federal allergy and infectious disease agency, with Jay Bhattacharya promising a major change in the agency’s priorities. NIAID will move away from biodefense research and toward immunology and diseases Americans face, while the institute’s biodefense programs transfer to the Department of War.
The shift follows a charged debate over pandemic-era research and the possibility that US-funded work in China was connected to COVID-19’s emergence. Anthony Fauci has denied that NIAID funded dangerous experiments at the Wuhan Institute of Virology. Scientists have questioned that account or said it is impossible to establish what the Chinese researchers were doing.
Bhattacharya and Powers say they have examined more than 8,000 grants for dangerous laboratory work. Powers says the institute should help answer medical questions, including about masks, rather than dictate policy. That is a useful distinction: research can inform public decisions without turning a science agency into a policymaking authority.
The agency’s new direction also emphasizes putting proven interventions into practice. Powers pointed to the transformation of HIV treatment, which now allows patients to manage the disease with a daily pill. NIAID’s challenge is to serve patients and produce trustworthy research without returning to the pandemic-era fights that damaged confidence in public health institutions.
NIH Ends Biodefense Focus as NIAID Gets New Director
The NIH has appointed John Powers to lead NIAID as Jay Bhattacharya redirects the agency away from biodefense research and toward basic immunology and infectious diseases Americans actually encounter. The stakes are substantial: biodefense programs made up more than $2.2 billion, about a third of the institute’s budget, in fiscal year 2025, and are now moving to the Department of War.
Bhattacharya says the agency has reviewed more than 8,000 research grants to screen for dangerous laboratory work. The change answers a central concern raised during the pandemic: whether taxpayer-supported research aimed at anticipating outbreaks went too far. Fauci has denied that NIAID funded dangerous experiments at the Wuhan Institute of Virology, but scientists have challenged that claim or said the work cannot be known with certainty.
Powers says NIAID should support research, not tell people what to do. He cited unresolved questions about masks as an example of issues research should address. That approach puts evidence before directives and draws a clearer line between a scientific agency and public policy.
Powers also wants the institute to concentrate on delivering interventions to people who need them, highlighting how HIV treatment has advanced to a once-daily pill. The test for the new leadership will be whether NIAID can pursue practical, relevant research while avoiding the risky biodefense portfolio Bhattacharya has rejected.
Reported by New York Post, The Washington Examiner.







